OBJECTIVES:To evaluate the use of standardized protocols for reflexing to broad, multigene panels in non-small cell lung cancer (NSCLC) and identify barriers that limit timely pathologist‑ordered biomarker reflex testing. METHODS:A cross-sectional survey was administered to a national sample of health care professionals involved in NSCLC biomarker testing. RESULTS:Of 111 respondents in the dataset, 77.5% reported using an institutional standardized protocol for comprehensive biomarker testing (CBT), and 88.4% of these protocols included reflexing to a multigene panel. Most respondents with reflex protocols indicated that 80% or more of newly diagnosed patients with NSCLC received CBT; however, fewer respondents reported that results were available before the oncology visit to select first‑line treatment. Pathologists were the primary ordering providers in institutions with standardized protocols. Respondents agreed that pathologist‑ordered reflex biomarker testing improves cancer care and supported Centers for Medicare & Medicaid Services (CMS) recognition of pathologists as ordering physicians for broad biomarker panels. Despite protocol adoption, respondents cited persistent barriers-including reimbursement, insurance authorization delays, and the Medicare 14-day rule. CONCLUSIONS:Locally standardized protocols incorporating reflex multigene panel testing have been reported and are associated with high rates of CBT. Institutional and operational barriers delay the availability of results and limit the impact of these protocols on first‑line treatment decisions. Clarifying CMS guidance on pathologists as valid ordering physicians for broad biomarker panels, strengthening coordination with multidisciplinary teams, addressing workflow constraints, and educating the laboratories and payers on pathologists having ordering authority may enhance the effectiveness and adoption of reflex biomarker testing models.
In advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations (Ex19del/L858R), intravenous amivantamab is approved for first-line treatment with lazertinib, and second-line treatment with carboplatin-pemetrexed. Subcutaneous amivantamab demonstrated noninferior pharmacokinetics and comparable efficacy with improved safety outcomes versus intravenous amivantamab in the PALOMA-3 trial. Venous thromboembolism (VTE) was also reduced when combined with prophylactic anticoagulation. In the COCOON trial, an enhanced prophylactic dermatologic regimen with intravenous amivantamab plus lazertinib treatment lowered grade ≥ 2 dermatologic adverse events (AEs). There are no studies combining subcutaneous administration with supportive care advancements in diverse participants with EGFR-mutated NSCLC. COPERNICUS (NCT06667076), an open-label, phase 2b study aims to evaluate the efficacy and safety of subcutaneous amivantamab with lazertinib (cohort 1) or with chemotherapy (cohort 2) while preventing and proactively managing VTE and dermatologic AEs in a multinational, clinically representative population with EGFR-mutated NSCLC. Eligible participants are adults with EGFR Ex19del/L858R NSCLC. A pragmatic study approach will be used to eliminate potential barriers to enrollment and increase diversity. Cohort 1 will enroll participants without prior systemic therapy to receive subcutaneous amivantamab and oral lazertinib. Cohort 2 will enroll participants with disease progression on EGFR-tyrosine kinase inhibitors to receive subcutaneous amivantamab and chemotherapy (carboplatin-pemetrexed). Both cohorts will receive enhanced dermatologic management; cohort 1 will receive prophylactic anticoagulation for the first 4 months of treatment. The primary endpoint is investigator-assessed progression-free survival. COPERNICUS is currently enrolling, with a planned enrollment in the United States of 300 and 30 participants in cohorts 1 and 2, respectively, plus 150 participants for cohort 1 in Europe. COPERNICUS uses a pragmatic study design to evaluate the efficacy and safety of subcutaneous amivantamab regimens combined with advancements in supportive care to prevent and proactively manage AEs in a diverse participant population.
Intravenous (IV) amivantamab is approved in combination with lazertinib for first-line (1L) NSCLC with EGFR Exon 19 deletions (Ex19del) or L858R substitution mutations, and in combination with chemotherapy for second-line (2L) EGFR Ex19del/L858R NSCLC, based on the favorable efficacy and safety results of the phase 3 MARIPOSA and MARIPOSA-2 clinical trials. Subcutaneous (SC) amivantamab demonstrated noninferior efficacy and improved safety vs IV amivantamab in the phase 3 PALOMA-3 study. Furthermore, a prophylactic anticoagulation regimen for venous thromboembolism (VTE) prevention and an enhanced regimen for managing dermatologic toxicities were validated in PALOMA-3 and the phase 2 COCOON study, respectively. However, no study has combined SC amivantamab with these advancements in supportive care in a representative, diverse group of participants with advanced EGFR-mutated NSCLC in the US. The open-label, 2-cohort, phase 2b COPERNICUS study (NCT06667076) aims to enroll a participant population that is demographically reflective of the overall US prevalence of EGFR-mutated NSCLC and to evaluate the efficacy and safety of SC amivantamab with lazertinib (Cohort 1) or chemotherapy (Cohort 2) while preventing and proactively managing VTE and dermatologic adverse events (AEs). Eligible participants are adults (≥18 years old) whose tumors harbor EGFR Ex19del or L858R. In Cohort 1, participants must not have received any prior systemic therapy and will receive SC amivantamab and oral lazertinib; in Cohort 2, participants must have had disease progression after EGFR-TKI monotherapy and will receive SC amivantamab and chemotherapy (carboplatin-pemetrexed). Both cohorts will receive enhanced dermatologic management, and Cohort 1 will receive prophylactic anticoagulation for the first 4 months of treatment. The primary endpoint is investigator-assessed progression-free survival. Secondary endpoints include incidence and severity of VTE and dermatologic AEs, overall survival, objective response rate, duration of response, and compliance with prophylactic medications. COPERNICUS is currently enrolling, with a planned enrollment of 300 and 30 participants in Cohorts 1 and 2, respectively. COPERNICUS aims to evaluate the efficacy and safety of SC amivantamab regimens using a pragmatic study design to enroll participants with diverse backgrounds and combine advancements in supportive care to prevent and proactively manage AEs. Balazs Halmos, Narjust Florez, Sarah Goldberg, Wade Iams, Xiuning Le, Ticiana Leal, Danny Nguyen, Luis E. Raez, Jonathan W. Riess, Joshua Sabari, David Bjork, Nichelle Stigger, Yichuan Xia, Paul Cifuentes, Denise D’Andrea, Andy L. Johnson, Melissa L. Johnson. A phase 2b study of subcutaneous amivantamab with lazertinib as first-line treatment, or with chemotherapy as second-line treatment, for EGFR-mutated non-small cell lung cancer (NSCLC): COPERNICUS [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT233.
Qualitative data that reflects patients’ experiences are the foundation of any patient-reported outcome measure (PROM) development and validation study; however, there is limited understanding of the type of data visualization techniques that facilitate communication of this data. The goal of this targeted literature review was to investigate data visualization methods that have been used in published PROM development and validation literature to report qualitative results. A literature search in OVID via MEDLINE was conducted among the top 10 non-disease-specific journals publishing PROM qualitative development and validation studies. Studies that reported qualitative methods to develop/validate a PROM and included data visualization in the form of tables or figures were included. Article characteristics and data visualization types were extracted. A total of 185 articles were included in data extraction. Most articles (n = 109, 59.1
e13713 Background: Overcoming barriers to care navigation remains a significant challenge in oncology. Patients often describe navigating a treacherous hike without a map, gear or a guide. Daswani developed a planning notebook with structured, evidence based sections for visit notes, treatment choices, and side effect and gratitude journaling during her 2020 journey with early stage breast cancer (BC). Initial distribution through patient advocacy groups (PAGs), hospital gift shops, and peer referral networks allowed feedback for iterative refinement. In 2022, the planner became the basis for an online web application (WebApp). The WebApp was tested for acceptability and utility. Methods: The WebApp enrollment was offered to rolling cohorts starting August 2024 with three core components: Map (interactive, disease-specific visual representation of the care journey), Gear (self-management tools for appointment preparation, symptom and medication tracking), and Guide (a searchable database of support services).Users were recruited through PAGs (in collaboration with Lungevity and Gilead Sciences, others) and clinician referrals. Platform engagement, navigation, and support service utilization were tracked. User experience was evaluated through analytics and questionnaires. Results: Of 99 users, 37 were patients (40% early-stage BC, 20% metastatic BC, 17% metastatic lung cancer, 22% other), 30 survivors, 13 caregivers, from 21 states. Average platform time was 38 minutes/user; 75% used human-help onboarding. 68% of patients used a Map: BC users focused on imaging interpretation and treatment planning; Lung cancer users prioritized biomarker testing and staging. Metastatic disease users engaged with treatment decision-making and symptom management. The platform connected an average of 16.7 support services/user: helplines (10%), peer navigation (8%), financial assistance (7%). Of users offered nurse support, 3% connected with nurses. 6 users completed surveys: average net promoter score 83 (scale -100 to +100). Conclusions: The WebApp provides disease-specific navigation support at time of patient decision making. Usage pattern analysis for BC and lung cancer patients shows the WebApp addresses unique disease-specific needs: biomarker testing in lung cancer and treatment sequencing in BC. Engagement duration suggests value in supporting complex decision-making for metastatic disease management. The oncology care team's reach is extended with the platform's ability to scale patient connection to relevant support services and extra clinical support. The WebApp and other digital navigation tools can enhance clinical care delivery by providing patients with consistent, evidence-based guidance while identifying those needing additional support. Ongoing refinement continues through user feedback and support service crowdsourcing, with vision for integration into routine care.